Loading
Led ALCYONE and the smouldering myeloma trials that showed treating early can delay progression to active disease.
María-Victoria Mateos (Salamanca) was principal investigator of ALCYONE, which established daratumumab with bortezomib-melphalan-prednisone in transplant-ineligible myeloma, and of the Spanish QuiRedex and the international AQUILA trials showing that treating high-risk smouldering myeloma with lenalidomide-dexamethasone or daratumumab delays progression and improves survival. She leads the Spanish Myeloma Group and IMWG guideline work.
Shares CD38, Monoclonal antibodies, Multiple myeloma and the tag myeloma.
Shares CD38, Monoclonal antibodies, Multiple myeloma and the tag myeloma.
Shares CD38, Monoclonal antibodies, Multiple myeloma and the tag myeloma.
Shares CD38, Monoclonal antibodies, Multiple myeloma and the tag myeloma.
Shares CD38, Multiple myeloma and the tag myeloma.
Shares CD38, Multiple myeloma and the tag myeloma.
Shares CD38, Multiple myeloma and the tag myeloma.
Shares Multiple myeloma and the tag myeloma.